公开(公告)号：US20240335462A1

公开(公告)日：2024-10-10

申请号：US18579862

申请日：2022-07-15

申请人： MEDSHINE DISCOVERY INC.

发明人： WANG Jianfei ,  Guangwen YANG ,  Zhihua AO ,  Jikui SUN ,  Yang ZHANG ,  Shuhui CHEN

IPC分类号： A61K31/675 ,  A61K31/44 ,  A61K31/444 ,  A61K31/50 ,  A61K31/501 ,  A61K31/506 ,  A61K31/541 ,  A61P17/06 ,  C07D213/82 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/14 ,  C07F9/58 ,  C07F9/6509 ,  C07F9/6558

CPC分类号： A61K31/675 ,  A61K31/44 ,  A61K31/444 ,  A61K31/50 ,  A61K31/501 ,  A61K31/506 ,  A61K31/541 ,  A61P17/06 ,  C07D213/82 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/14 ,  C07F9/58 ,  C07F9/650905 ,  C07F9/65583

摘要： Provided are a sulfur/phosphorus-containing aryl compound and an application thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240300974A1

公开(公告)日：2024-09-12

申请号：US18516014

申请日：2023-11-21

申请人： Genentech, Inc.

发明人： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC分类号： C07D498/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D498/04 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00

摘要： The invention provides novel compounds having the general formula I:




wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20240300945A1

公开(公告)日：2024-09-12

申请号：US18571578

申请日：2022-06-17

申请人： NANJING WELLBEST PHARMACEUTICAL CO., LTD

发明人： Min CHEN ,  Yongping WU

IPC分类号： C07D471/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61P11/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/10 ,  A61P17/14 ,  A61P19/02 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D471/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61P11/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/10 ,  A61P17/14 ,  A61P19/02 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14

摘要： Disclosed a CLY series compound, a preparation method therefor and the use thereof in the preparation of drugs. The CLY series compound can significantly prolong the survival time of acute GVHD mice, and can reduce clinical symptoms, exhibiting a therapeutic effect on acute GVHD; in a pulmonary fibrosis mouse model, same can obviously reduce the levels of MMP-2 and MMP-9 in the lung tissue, increase the levels of TIMP-1 and VEGF, and simultaneously increase the levels of SOD and CAT enzymes in peripheral blood; and same can also improve the arthritis symptoms of rheumatoid arthritis mice by means of reducing the level of IL-17 in peripheral blood and increasing inflammatory indexes such as IL-10. The compound can be used alone or in combination with other drugs, and provides a new drug choice for the treatment of the above diseases.

公开(公告)号：US20240299315A1

公开(公告)日：2024-09-12

申请号：US18298012

申请日：2023-04-10

申请人： Liangdan Sun

发明人： Qi Zhen ,  Weiwei Chen ,  Zhuo Li ,  Yirui Wang ,  Liangdan Sun

IPC分类号： A61K31/122 ,  A61P17/06

CPC分类号： A61K31/122 ,  A61P17/06

摘要： A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided and belongs to the field of protein inhibitory medicines. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as KD=1.56E−6M and KD=5.12E−6M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.

公开(公告)号：US12076403B2

公开(公告)日：2024-09-03

申请号：US17993799

申请日：2022-11-23

申请人： Bausch Health Ireland Limited

发明人： Arturo Angel ,  Gordon Dow

IPC分类号： A61K47/14 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K9/14 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

CPC分类号： A61K47/14 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

摘要： Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

公开(公告)号：US12042558B2

公开(公告)日：2024-07-23

申请号：US16426492

申请日：2019-05-30

申请人： ARCUTIS BIOTHERAPEUTICS, INC.

发明人： David W. Osborne

IPC分类号： A61K31/277 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K31/122 ,  A61K31/17 ,  A61K31/194 ,  A61K31/366 ,  A61K31/44 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/60 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/69 ,  A61P17/06 ,  A61K45/06

CPC分类号： A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K31/122 ,  A61K31/17 ,  A61K31/194 ,  A61K31/366 ,  A61K31/44 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/60 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/6903 ,  A61P17/06 ,  A61K45/06

摘要： Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.

公开(公告)号：US20240226196A9

公开(公告)日：2024-07-11

申请号：US18546321

申请日：2022-02-17

申请人： Axisbiotix Limited

发明人： Catherine O'Neill

IPC分类号： A61K35/745 ,  A61K9/00 ,  A61K35/744 ,  A61K35/747 ,  A61P17/00 ,  A61P17/06

CPC分类号： A61K35/745 ,  A61K9/009 ,  A61K9/0095 ,  A61K35/744 ,  A61K35/747 ,  A61P17/00 ,  A61P17/06 ,  A61K2035/115

摘要： The present invention relates to a composition for use in the treatment and/or prevention of a dry and/or sensitive skin condition in a subject. The composition comprises at least two bacterial species which decrease the levels of interleukin-17 and/or interleukin-23 in the subject, and/or increase the levels of interleukin-10 in the subject and/or improve gut barrier function in the subject. The at least two bacterial species may comprise Bifidobacterium animalis, Lactobacillus brevis, Lactobacillus reuteri and/or Lactococcus lactis.

公开(公告)号：US20240209102A1

公开(公告)日：2024-06-27

申请号：US18523048

申请日：2023-11-29

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jamie M. Orengo ,  Jeanne Allinne ,  Andrew J. Murphy ,  George D. Yancopoulos

IPC分类号： C07K16/28 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P9/14 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/715 ,  C07K16/24

CPC分类号： C07K16/2866 ,  A61K38/1793 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P9/14 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/7155 ,  C07K16/244 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/00

摘要： The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.

公开(公告)号：US12016921B2

公开(公告)日：2024-06-25

申请号：US17058537

申请日：2019-05-29

申请人： Abcentra, LLC

发明人： Bertrand C. Liang ,  Stacey Ruiz ,  Christopher John Farina

IPC分类号： A61P17/06 ,  A61K39/395 ,  C07K16/18 ,  A61K9/00 ,  A61K31/203 ,  A61K31/573 ,  A61K31/593 ,  A61K35/04 ,  A61K39/00 ,  A61K45/06 ,  C07K14/775

CPC分类号： A61K39/3955 ,  A61P17/06 ,  C07K16/18 ,  A61K9/0019 ,  A61K31/203 ,  A61K31/573 ,  A61K31/593 ,  A61K35/04 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K45/06 ,  C07K14/775 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565

摘要： Compositions and methods for treating a subject with psoriasis are provided, including an inhibitor of oxidized low density lipoprotein (LDL), malondialdehyde-modified epitope in LDL or native LDL for administration. Exemplary inhibitors of oxidized or malondialdehyde-modified LDL include orticumab, a variant antibody or peptides capable of binding oxidized or malondialdehyde-modified LDL, which results in improvement in conditions of psoriasis even in patients that are refractory to ultraviolet A/B therapy and topical steroids.

公开(公告)号：US20240197661A1

公开(公告)日：2024-06-20

申请号：US18492882

申请日：2023-10-24

申请人： Arbor Pharmaceuticals, LLC

发明人： Peter A. VIRSIK ,  Sami KARABORNI ,  Laura Elizabeth BAUER ,  Chen MAO ,  Ching Wah CHONG

IPC分类号： A61K31/197 ,  A61K9/20 ,  A61K9/28 ,  A61P17/06

CPC分类号： A61K31/197 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2866 ,  A61P17/06

摘要： Methods of treating psoriasis with sustained release compression coated tablet dosage forms comprising certain MHF prodrugs are provided.